Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial of pazopanib before surgery for kidney cancer - PANTHER
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at pazopanib before surgery for kidney cancer that has spread to another part of the body.
The most common type of kidney cancer is renal cell cancer. There are several different types of renal cell cancer. The most common is called clear cell cancer.
Pazopanib is a type of biological therapy called a tyrosine kinase inhibitor (TKI for short). TKIs block tyrosine kinase, which is a chemical messenger that sends messages telling cells to divide and grow. Blocking the effect of tyrosine kinase may stop cancer cells growing.
In this trial, researchers want to find out if there is a benefit to starting pazopanib before surgery.
The aims of the trial are to find out
- If having pazopanib before surgery to remove your kidney helps people with kidney cancer that has spread to another part of the body
- What the complications of surgery could be after having pazopanib
Who can enter
You may be able to enter this trial if you
- Have clear cell cancer that has spread to another part of the body
- Have satisfactory blood test results
- Are well enough to be up and about for at least half the day (performance status 0, 1 or 2)
- Are willing to use reliable contraception during treatment and for 3 months after if there is any chance you or your partner could become pregnant
- Are at least 18 years old
You cannot enter this trial if you
- Have already had treatment for kidney cancer that reaches your whole body (
systemic treatment)– you may join the trial if you had radiotherapy to relieve symptoms of your kidney cancer
- Have already had surgery to remove your kidney
- Have had a heart attack or stroke in the last 6 months
- Have a serious heart problem such as heart failure or heart pain (angina) that needs treatment
- Have a problem with your heart rhythm that is not controlled with medication
- Have high blood pressure that is not controlled with medication
- Have problems with your
digestive systemsuch as ulcerative colitis, peptic ulcer or inflammatory bowel disease, or anything else that could affect the way you absorb tablets
- Have a bleeding problem
- Have had another cancer in the last 5 years that needed treatment apart from prostate cancer that was only in the prostate gland (localised) and did not need treating with hormone therapy
- Have another medical condition that could affect you taking part in this trial
This is a phase 2 trial. It will recruit about 95 people from around the UK.
Everyone taking part will have pazopanib. It is a tablet you take once a day. You take pazopanib for 12 to16 weeks before surgery to remove your kidney. You stop taking it 2 days before surgery and start taking it again at least 2 weeks after surgery.
If you are not well enough to have surgery after 14 weeks of pazopanib, you can continue taking it as long as your doctor feels it is helping you.
Whether or not you have surgery, you can continue having pazopanib as long as you don’t have bad side effects and it is still helping you.
You will see the doctor and have some tests before having treatment. These tests include
- A physical examination
- Blood tests
- CT scan and possibly MRI scan and PET scan
- Heart trace –
- Ultrasound of the heart –
You see the doctor after 4 weeks of treatment to see how you are and to check if you are having any side effects.
At 8 and 12 weeks you see the doctor for blood tests. You also have a heart trace (ECG) at week 12.
Before surgery you see the doctor for a physical examination and blood tests.
Two weeks after surgery you see the doctor for a physical examination and blood tests before you start taking pazopanib again.
You see the doctor at 4 and 6 weeks after restarting the treatment and have blood tests. At 6 weeks you have a CT scan.
After surgery you see the doctor every 6 weeks while having pazopanib. If you agree the trial team will then contact you every 4 months to see how you are.
The most common side effects of pazopanib are
- Weight loss
- Loss of hair colour or Hair loss
- High blood pressure
- Feeling or being sick
- Tummy pain
- A drop in blood cells causing an increased risk of infection, bruising or bleeding
- Change in taste
- Changes to your
- Changes to your heart
- Changes to your liver
- Rash and changes in skin colour
- Protein in your urine
- Chest pain
You can find more information about pazopanib on CancerHelp UK.
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Prof Thomas Powles
Experimental Cancer Medicine Centre (ECMC)
Queen Mary University of London